166,375 Shares in Genfit S.A. (NASDAQ:GNFT) Bought by Millennium Management LLC

Millennium Management LLC acquired a new stake in Genfit S.A. (NASDAQ:GNFT - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 166,375 shares of the company's stock, valued at approximately $611,000. Millennium Management LLC owned 0.33% of Genfit as of its most recent filing with the Securities & Exchange Commission.

Genfit Trading Up 0.2%

Genfit stock traded up $0.01 during mid-day trading on Wednesday, reaching $4.25. The stock had a trading volume of 12,920 shares, compared to its average volume of 11,306. The company has a current ratio of 3.74, a quick ratio of 3.74 and a debt-to-equity ratio of 0.61. Genfit S.A. has a fifty-two week low of $2.55 and a fifty-two week high of $6.42. The stock's 50-day simple moving average is $3.96 and its 200-day simple moving average is $3.81.

Genfit Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.